Bank Of America Corp Gemini Therapeutics, Inc. Transaction History

Bank Of America Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.31 - $2.01 $7 - $12	6 Added 2.5%	246 $0
Q2 2022 Aug 12, 2022	SELL	$1.22 - $1.73 $8,419 - $11,938	-6,901 Reduced 96.64%	240 $0
Q1 2022 May 16, 2022	SELL	$1.29 - $3.08 $17,569 - $41,949	-13,620 Reduced 65.6%	7,141 $10,000
Q4 2021 Feb 08, 2022	BUY	$2.39 - $4.0 $22,611 - $37,844	9,461 Added 83.73%	20,761 $61,000
Q3 2021 Nov 15, 2021	SELL	$3.3 - $6.32 $13,523 - $25,899	-4,098 Reduced 26.61%	11,300 $45,000
Q2 2021 Sep 13, 2021	BUY	$6.32 - $14.02 $97,315 - $215,879	15,398 New	15,398 $99,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.